Skip to main content
SpringerLink
Log in

Treatment of Metastatic Head and Neck Cancer: Chemotherapy and Novel Agents

  • Chapter
Head and Neck Cancer

Part of the book series: Cancer Treatment and Research ((CTAR,volume 114))

Conclusions

Recurrent HNSCC remains a complex and frustrating disease. Given the experience of the past decade, expectations that improvements in outcome with traditional cytotoxins will ensue have been dampened. Molecularly targeted agents are under active investigation and hold more promise for improving the plight of our patients. These agents will likely have the greatest impact when used in combination with chemotherapy. It seems unlikely, however, that we will begin to cure these patients who currently have a life expectancy of 6–9 months. Palliation will remain the intent of therapy in the recurrent setting and for this reason it is paramount that we focus on these effects in our research.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Jemal A, Thomas A, Murray T, Thun M. Cancer Statistics, 2002. CA Cancer J Clin 2002; 52:23–47.

    Article  PubMed  Google Scholar 

  2. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK: Medical progress: head and neck cancer. N. Engl J Med 328: 184–194, 1993.

    Article  PubMed  CAS  Google Scholar 

  3. Mitchell MS, Wawro NW, DeConti RC, et al: Effectiveness of high-dose infusion of methotrexate followed by leucovorin in carcinoma of the head and neck. Cancer Res 1968;28:108.

    Google Scholar 

  4. Kirkwood JM, Millder D, Pitman S, et al: Initial high dose methotrexate-leucovorin in advanced squamous carcinoma of the head and neck. Proc Am Assoc Cancer Res 1978;19:398.

    Google Scholar 

  5. Levitt M, Mosher MB, DeConti RC, et al: Improved therapeutics of methotrexate with leucovorin rescue. Cancer Res 1973;33:1729.

    PubMed  CAS  Google Scholar 

  6. Woods RL, Fox RM, Tattersall MHN. Methotrexate treatment of advanced head and neck cancers: a dose-response evaluation. Cancer Treat Rep 1981;65:155.

    PubMed  Google Scholar 

  7. DeConti RC, Schoenfeld D. A randomized prospective comparison of intermittent methotrexate, methotrexate with leucovorin, and a methotrexate combination in head and neck cancer. Cancer 1981;48:1061.

    Google Scholar 

  8. Taylor SG, McGuire WP, Hauck WW, et al: A randomized comparison of high-dose infusion methotrexate versus standard-dose weekly therapy in head and neck squamous cancer. J Clin Oncol 1984;2:1006.

    PubMed  Google Scholar 

  9. Urba SG. Palliative chemotherapy for recurrent or metastatic head and neck cancer. ASCO Educational Book, Spring 2002,573–77.

    Google Scholar 

  10. Pinto HA, Jacobs CJ: Chemotherapy for recurrent and metastatic head and neck cancer. Hematol/Oncol Clin North Am 1991;5:667.

    CAS  Google Scholar 

  11. Al-Sarraf M. Chemotherapeutic management of head and neck cancer. Cancer Metastasis Rev 1987;6:191.

    Google Scholar 

  12. Forastiere AA, Takasugi BJ, Baker SR, et al: High dose cisplatin in head and neck cancer. Cancer Chemother Pharmacol 1987;19:155.

    Article  PubMed  CAS  Google Scholar 

  13. Havlin KA, Kuhn JG, Myers JW, et al: High-dose cisplatin for locally advanced or metastatic head and neck cancer. Cancer 1989;63:423.

    PubMed  CAS  Google Scholar 

  14. Veronesi A, Zagonel V, Rirelli U, et al: High dose versus low dose cisplatin in advanced head and neck squamous carcinoma. A randomized study. J Clin Oncol 1985;3:1105.

    CAS  Google Scholar 

  15. Al-Sarraf M. Management strategies in head and neck cancer: the role of carboplatin. In: Bunn PA, Canetta R, Ozols RF, Rozencqeig M, eds. Current perspectives and future directions. Philadelphia: WB Saunders, 1990.

    Google Scholar 

  16. Kish JA, Ensley JF, Jacobs J, et al: A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. Cancer 56:2740–2744, 1985.

    PubMed  CAS  Google Scholar 

  17. Forastiere AA, Shank D, Neuberg D, Taylor SG 4th, DeConi RC, Adams G. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group Trial (PA390). Cancer 1998, 82:2270–2274.

    Article  PubMed  CAS  Google Scholar 

  18. McWilliams JE, Cohen II, Everts EC, Andersen PE, Henner WD. A phase II trial of lower dose paclitaxel in recurrent and metastatic and neck squamous cell carcinoma (HNSCC) (abstract). Proc Am Soc Clin Oncol 1998, 17:407a.

    Google Scholar 

  19. Dreyfuss AI, Clark JR, Norris CM, et al: Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 1996; 14:1672–8.

    PubMed  CAS  Google Scholar 

  20. Catimel G, Verweij J, Mattijssen V, et al: Docetaxel: an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 1994;5:533.

    PubMed  CAS  Google Scholar 

  21. Vermorken JB, Catimel G, De Mulder P, Hoekman K, Hupperts P, Ruggeri E, et al. randomized phase II trial of weekly methotrexate versus two schedules of triweekly paclitaxel (Taxol) in patients with metastic or recurrent squamous cell carcinoma of the head and neck (abstract) Proc ASCO 1999, 18:295a.

    Google Scholar 

  22. Jacobs C; Lyman G; Velez-Garcia E, et al: A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10(2):257–63, 1992

    PubMed  CAS  Google Scholar 

  23. Forastiere AA; Metch B; Schuller DE, et al: Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 10(8):1245–51, 1992

    PubMed  CAS  Google Scholar 

  24. Clavel M, Vermorken JB, Cognetti F, et al: Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 1994;5:521.

    PubMed  CAS  Google Scholar 

  25. Browman GP, Cronin L. Standard chemotherapy in squamous cell head and neck cancer: what we have learned from randomized trials. Semin Oncol 1994;21:311.

    PubMed  CAS  Google Scholar 

  26. Hussain M; Gadgeel S; Kucuk O, et al: Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck. Cancer 1999;86(11):2364–9.

    Article  PubMed  CAS  Google Scholar 

  27. Shin DM; Glisson BS; Khuri FR, et al: Phase II trial ofpaclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998;16(4):1325–30.

    PubMed  CAS  Google Scholar 

  28. Thodtmann F, Theisis F, Kemmerich M, Heinrich B. Laubenbacher C. Quasthoff S, et al. Clinical phase II evaluation of paclitaxel in combination with cisplatin in metastic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol 1998, 9:335–337.

    PubMed  CAS  Google Scholar 

  29. Janinis J, Papadakou M, Xidakis E, et al. Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study. Am J Clin Oncol. 2000;23(2):128–31.

    Article  PubMed  CAS  Google Scholar 

  30. Glisson BS, Murphy BA, Frenette G, Khuri FR, Forastiere AA. Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol 2002;20:1593–1599.

    Article  PubMed  CAS  Google Scholar 

  31. Forastiere AA, Leong T, Rowinsky E, Murphy BA, Vlock DR, DeConti RC, Adams GL. Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin Oncol 2001;19:1088–1095.

    PubMed  CAS  Google Scholar 

  32. Murphy B, Li Y, Cella D, Karnad A, Hussain M, Forastiere A. Phase III study comparing cisplatin (C) & 5-flurouracil (F) versus cisplatin & paclitaxel (T) in Metastatic/Recurrent Head & Neck Cancer (MHNC). (abstract 894) Proc ASCO 2001, 20:224a.

    Google Scholar 

  33. Fountzilas G, Athanassiades A, Kalogera-Fountzila A, Samantas E, Bacoyiannis C, et al. Paclitaxel in combination with carboplatin or gemcitabine for the treatment of advanced head and neck cancer. Semin Oncol 1997;24(suppl 19):S19-28–S19-32.

    Google Scholar 

  34. Stathopoulos GP, Rigatos S, Papakostas P, Fountzilas G. Effectiveness of paclitaxel and carboplatin combination in heavily pretreated patients with head and neck cancers. Eur J Cancer 1997; 33:1780–1783.

    Article  PubMed  CAS  Google Scholar 

  35. Salomen DS, Brandt R, Ciardiello F, et al: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol/Hematol 1995;19:183–232.

    Google Scholar 

  36. Harari PM, Huang SM: Modulation of molecular targets to enhance radiation. Clin Cancer Res 2000, 6: 323–325

    PubMed  CAS  Google Scholar 

  37. Thompson DM, Gill GN: The EGF receptor: structure, regulation and potential role in malignancy. Cancer Surv 1985, 4: 767–788

    PubMed  CAS  Google Scholar 

  38. Shin DM, Ro JY, Hong WK, et al: Dysregulation of epidermal growth factor receptor expression in multistep process of head and neck tumorigenesis. Cancer Res 1994; 54: 3153–3159.

    PubMed  CAS  Google Scholar 

  39. Gullick WJ. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 1991;47:87–98.

    PubMed  CAS  Google Scholar 

  40. Lofts FJ, Gullick WJ. C-erbB2 amplification and overexpression in human tumors, in Dickson RB, Lippman ME (eds.): Genes, Oncogenes, and Hormones: Advances in Cellular and Molecular Biology of Breast Cancer. Boston: Kluwer Academic Publishers, 1991, pp 161–179

    Google Scholar 

  41. Bruns CJ, Harbison MT, Davis DW, et al: Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 2000; 1936–1948.

    Google Scholar 

  42. Fischer-Colbrie J, Witt A, Heinzl H, et al: EGFR and steroid receptors in ovarian carcinoma: Comparison with prognostic parameters and outcome of patients. Anticancer Res 1997;17:613–620.

    PubMed  CAS  Google Scholar 

  43. Chow N-H, Liu H-S, Lee EI, et al: Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. Anticancer Res 1997; 17:1293–1296.

    PubMed  CAS  Google Scholar 

  44. Ke LD, Adler-Storthz K, Clayman GL, et al: Differential expression of epidermal growth factor receptor in human head and neck cancers. Head Neck 1998;20:320–327.

    Article  PubMed  CAS  Google Scholar 

  45. Grandis JR, Melhem MF, Barnes EL, et al: Quantitative immunohistochemical analysis of transforming growth factor-α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996;78:1284–1292.

    Article  CAS  Google Scholar 

  46. Modjahedi H, Affleck K, Stubberfield C, et al: EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in human squamous cell carcinoma HN5. Int J Oncol 1998;13:335–342.

    Google Scholar 

  47. He Y, Zeng Q, Drenning SD, et al: Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. J Natl Cancer Inst 1998;90:1080–1087.

    Article  PubMed  CAS  Google Scholar 

  48. Huang S-M, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999;35–1940.

    Google Scholar 

  49. Baselga J, Norton L, Masui H, et al: Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993;27–1333.

    Google Scholar 

  50. Baselga J; Pfister D; Cooper MR, et al: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000;904–14.

    Google Scholar 

  51. Shin DM, Donato NJ, Cooper M, et al: Epidermal growth factor receptor targeted therapy with humanized chimeric monoclonal antibody, C225 in combination with cisplatin in patients with head and neck cancer. Clin Cancer Res 2001:1204–13.

    Google Scholar 

  52. Kies MS, Arquette MA, Nabell L, Quinn D, Shin D, Needle MM, Waksal H, Hong WK, Herbst RS. Final report of the efficacy and safety of the anti-epidermal growth factor antibody Erbitux (IMC-C225), in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy. Proc Am Soc Clin Oncol 21:232a, 2002 (abstr 925)

    Google Scholar 

  53. Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R, Gascon P, Muesser M, Harstrick A, Eckardt A. Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen. Proc Am Soc Clin Oncol 21:226a, 2002 (abstr 900)

    Google Scholar 

  54. Burtness BA, Li Y, Flood W, Mattar BI, Forastiere AA. Phase III trial comparing cisplatin (C) + placebo (P) to C + anti-epidermal growth factor antibody (EGF-R) C225 in patients (pts) with metastic/recurrent head & neck cancer (HNC). Proc Am Soc Clin Oncol 21:226a, 2002 (abstr 901)

    Google Scholar 

  55. Baselga J, Averbuch SD. ZD1839 (‘Iressa’) as an anticancer agent. Drugs. 60Suppl 1:33–40; discussion 41–2, 2000

    PubMed  CAS  Google Scholar 

  56. Al-Hazzaa AA, Bowen ID, Birchall MA, et al: p53-independent apoptosis induced by cisplatin and enhanced by the combination of cisplatin with ZD1839 (Iressa) an EGFR-TK inhibitor in an oral squamous cell carcinoma cell line. Proceedings AACR-NCI-EORTC International Conference, 2001 348 (abstract).

    Google Scholar 

  57. Huang S, Harari PM: Modulation of radiation response and tumor-induced angiogenesis following EGFR blockade by ZD1839 (Iressa) in human squamous cell carcinomas. Proceedings AACR-NCI-EORTC International Conference, 2001 259 (abstract).

    Google Scholar 

  58. Kris M, Ranson M, Ferry D, et al.: Phase I study of oral ZD1839 (Iressa), a novel inhibitor of epidermal growth factor tyrosine kinase (EGFR-tK): evidence of good tolerability and activity. Clin Cancer Res 5:3749S.

    Google Scholar 

  59. Negoro S, Nakagawa K, Fukuoka M, et al.: Final results of a phase I intermittent dose-escalation trial of ZD1839 (Iressa) in Japanese patients with various solid tumors. Proc Am Soc Clin Oncol 20:324a, 2001.

    Google Scholar 

  60. Baselga J, Herbst R, LoRusso P, et al. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFRj-TKI), in patients with five selected tumor types: evidence of activity and good tolerability. Proc Am Soc Clin Oncol 19:1771 (686), 2000.

    Google Scholar 

  61. Ferry D, Hammond L, Ranson M, et al. Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (Egfr-tki), shows evidence of good tolerability and activity: final results from a phase I study. Proc Am Soc Clin Oncol 19:3a, 2000. (Abstract 5E)

    Google Scholar 

  62. Baselga J, Yano S, Giaccone G, et al: Initial results from a phase II trial of ZD1839 (Iressa) as second-and third-line monotherapy for patients with advanced non-small cell lung cancer (IDEAL-1). Proceedings AACR-NCI-EORTC International Conference, 2001 630A (abstract).

    Google Scholar 

  63. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, et al. A phase II trial of ZD1839 (‘IRESSA’) in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum-and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol 21:292a (1166), 2002.

    Google Scholar 

  64. Cohen EE, Rosen F, Dekker A, Bajda C, Stenson K, Shulman KL, Lamont E, Kozoloff M, Vokes EE. Phase II study of ZD 1839 (Iressa) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol 21:225a, 2002. (abstract 899)

    Google Scholar 

  65. Senzer NN, Soulieres D, Siu L, et al: Phase II evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck. Proc Amer Soc Clinic One 2001, 6 (abstract).

    Google Scholar 

  66. Glisson S, Huber J, Gaugler M, et al: Smokeless Tobacco Induced Oral Cavity Tumors in Kentucky Have a High Incidence of H-ras Mutations. ASCO Volume 17, 1998

    Google Scholar 

  67. Sepp-Lorenzino L, Ma Z, Rands E, et al: A peptidomimetic inhibitor of farnesylprotein transferase blocks the anchorage-dependent and-independent growth of human tumor cell lines. Cancer Res 55(22):5302–9, 1995

    PubMed  CAS  Google Scholar 

  68. Moasser MM, Sepp-Lorenzino L, Kohl NE, et al: Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci U S A. 1998;95; 1369–74, 1998

    Article  PubMed  CAS  Google Scholar 

  69. Kies MS, Clayman GL, El-Naggar AK, et al: Induction therapy with SCH 66336, a farnesyltransferase inhibitor, in squamous cell carcinoma (SCC) of the head and neck. Proc Am Soc Clin Oncol 2001 896 (abstract)

    Google Scholar 

  70. Kim ES, Glisson BS, Meyers ML, et al: A phase I/II study of the farnesyl transferase inhibitor (FTI) SCH66336 with paclitaxel in patients with solid tumors. Proc Amer Assoc Cancer Res 2001, 2629 (abstract)

    Google Scholar 

  71. Kim ES, Kies MS, Fossella FV, et al: A phase I/II study of farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) with paclitaxel in taxane-refractory/resistant patients with non-small cell lung cancer: final report. Proc Amer Assoc Cancer Res 2002, (abstract) submitted and accepted.

    Google Scholar 

  72. Boyle JO, Hakim J, Koch W, et al: The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 1993;53:4477–4480.

    PubMed  CAS  Google Scholar 

  73. Brennan JA, Boyle JO, Koch WM, et al: Association between cigarette smoking and mutation of the p53 gene in squamous cell carcinoma of the head and neck. N Engl J Med 1995;332:712–717.

    PubMed  CAS  Google Scholar 

  74. Werness BA, Levine AJ, Howley PM: Association of human papillomavirus type 16 and 18 E6 proteins with p53. Science 1990;248:76–79.

    PubMed  CAS  Google Scholar 

  75. Gillison ML, Koch WM, Capone RB, et al: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92:709–720.

    Article  PubMed  CAS  Google Scholar 

  76. Cabelguenne A, Blons H, de Waziers I, et al: p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol 2000; 18:1465–73.

    PubMed  CAS  Google Scholar 

  77. Bischoff JR, Kirn DH, Williams A, et al: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274:373–376.

    Article  PubMed  CAS  Google Scholar 

  78. Heise C, Sampson-Johannes A, Williams A, et al: ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997; 3:639–45.

    Article  PubMed  CAS  Google Scholar 

  79. Kirn D, Hermiston T, McCormick F. ONYX-015: clinical data are encouraging. Nat Med 1998; 4:1341–2.

    Article  PubMed  CAS  Google Scholar 

  80. Kirn D, et ai: A phase II trial of intratumoral injection with an E1B-deleted adenovirus, ONYX-015, inpatients with recurrent, refractory head and neck cancer. Proc am Soc Clin Oncol 1998; 17:391a

    Google Scholar 

  81. Ganly I, Eckhardt SG, Rodriguez GI, et al: A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 2000;6:798–806.

    PubMed  CAS  Google Scholar 

  82. Ries SJ; Brandts CH; Chung AS, et al: Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant d11520 (ONYX-015). Nat Med 2000;6:1128–33, 2000.

    PubMed  CAS  Google Scholar 

  83. Lowe SW, Ruley HE, Jacks T, et al: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;24:957–67.

    Google Scholar 

  84. Lowe SW, Bodis S, McClatchey A, et al: p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807–10.

    PubMed  CAS  Google Scholar 

  85. Sanchez-Prieto R, Quintanilla M, Cano A, et al: Carcinoma cell lines become sensitive to DNA-damaging agents by the expression of the adenovirus E1 A gene. Oncogene 1996;5;13(5):1083–92.

    PubMed  Google Scholar 

  86. Lowe SW, Ruley HE: Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev 1993;7:535–45.

    PubMed  CAS  Google Scholar 

  87. Barker DD, Berk AJ: Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 1987;156:107–21.

    Article  PubMed  CAS  Google Scholar 

  88. Khuri FR, Nemunaitis J, Ganly I, et al: A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000;6:879–85.

    Article  PubMed  CAS  Google Scholar 

  89. Nemunaitis J, Khuri F, Ganly I, et al: Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001;19:289–98.

    PubMed  CAS  Google Scholar 

  90. Nemunaitis J, Cunningham C, Buchanan A, et al: Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther 2001;8:746–59.

    Article  PubMed  CAS  Google Scholar 

  91. Horio Y, Hasegawa Y, Sekido Y, et al: Synergistic effects of adenovirus expressing wild-type p53 on chemosensitivity of non-small cell lung cancer cells. Cancer Gene Ther 2000;7:537–44.

    Article  PubMed  CAS  Google Scholar 

  92. Ishida S, Yamashita T, Nakaya U, et al: Adenovirus-mediated transfer of p53-related genes induces apoptosis of human cancer cells. Jpn J Cancer Res 2000; 91:174–80.

    PubMed  CAS  Google Scholar 

  93. Clayman GL, El-Naggar AK, Lippman SM, et al: Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998; 16:2221–32.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030

    Edward S. Kim & Bonnie S. Glisson

Authors
  1. Edward S. Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bonnie S. Glisson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Evanston Northwestern Healthcare, Evanston, IL

    Brockstein Bruce M.D.  & Masters Gregory M.D.  & 

  2. Robert H. Lurie Cancer Center of Northwestern University, Feinberg School of Medicine, Chicago, IL

    Brockstein Bruce M.D.  & Masters Gregory M.D.  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Kluwer Academic Publishers

About this chapter

Cite this chapter

Kim, E.S., Glisson, B.S. (2004). Treatment of Metastatic Head and Neck Cancer: Chemotherapy and Novel Agents. In: Bruce, B., Gregory, M. (eds) Head and Neck Cancer. Cancer Treatment and Research, vol 114. Springer, Boston, MA. https://doi.org/10.1007/0-306-48060-3_12

Download citation

  • DOI: https://doi.org/10.1007/0-306-48060-3_12

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4020-7336-6

  • Online ISBN: 978-0-306-48060-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation